CATEGORIES: Research
voice activated technology

HNF Partners with True Reply, the Future of Data Collection: Voice Activated Technology (VAT)

by | Dec 8, 2018 | 0 comments

True Reply Logo

  • Accessible and innovative new platform allows for HNF to capture the patient’s experience with CMT in their own words
  • Respondents call into a toll free number where they are asked a series of questions
  • Data is then processed with Artificial Intelligence powered analytics to reveal telling insights
  • Pilot study was launched in 2017 at HNF’s Patient-Centered CMT/HNPP Pain Summit (funded by PCORI’s Eugene Washington Engagement Award #EAIN-7238) where patients were asked to use one word to describe their disease. PAIN was the #1 response
  • Internal Review Board (IRB) approved study through HNF’s patient registry, GRIN, captured 292 patient testimonies in their own voice and 27 of these testimonies were presented to the FDA during the Externally-led PFDD Meeting

true reply graphic

So go ahead and speak up.

YOUR VOICE HAS NEVER BEEN MORE POWERFUL THAN NOW!

Join GRIN

Learn more on this topic

Related Blog Posts

Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency

by | Mar 18, 2020 | , | 5 Comments

United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to its lead drug candidate, PXT3003, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A) in patients 16 years and older.

Pharnext raises € 7.7 million in a private placement

by | Mar 11, 2020 | , , | 0 Comments

Pharnext SA (FR0011191287 – ALPHA) (the “Company”), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, today announced a capital raise of circa € 7.7 million by way of issuance of 1,799,061 new ordinary shares (the “New Shares”) with one warrant attached each (together with the New Shares, the “ABSA”).

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news